Actinium-225 Anti-CD45 Antibody Composition Patent Granted
Summary
The USPTO granted patent US12605472B2 to Actinium Pharmaceuticals, Inc. on April 21, 2026, covering compositions and methods for treating hematological diseases using actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose. The patent claims 23 compositions and methods of use for treating hemoglobinopathies and hematological malignancies.
“The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose.”
What changed
The USPTO issued patent US12605472B2 to Actinium Pharmaceuticals, Inc. for a radiolabeled anti-CD45 antibody (BC8) linked to actinium-225, a potent alpha-emitting radionuclide. The patented compositions are formulated as single-patient doses wholly deliverable in a single administration, for use alone or in combination with bone marrow transplant, adoptive cell therapies, or other immunotherapeutics. The patent covers methods of treating hemoglobinopathies and hematological diseases including hematological malignancies.
Affected parties include biopharmaceutical companies developing targeted radiopharmaceuticals for hematological cancers, as well as academic institutions and researchers in the radiopharmaceutical space. The grant establishes Actinium Pharmaceuticals' intellectual property position in the actinium-225 anti-CD45 space, which may affect licensing strategies and competitive development timelines for similar therapeutic approaches.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof
Grant US12605472B2 Kind: B2 Apr 21, 2026
Assignee
Actinium Pharmaceuticals, Inc.
Inventors
Dale Ludwig, Sandesh Seth
Abstract
Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.
CPC Classifications
A61K 51/1027 A61K 41/0038 A61K 2039/505 A61K 35/28 A61K 51/1093 A61K 51/1096 A61P 7/00 A61P 35/00 A61P 37/04 A61P 35/02 C07K 16/289 C07K 2317/90
Filing Date
2020-09-17
Application No.
17761579
Claims
23
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.